Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study Comparing CNTO 1275 vs Etanercept in Moderate to Severe Plaque Psoriasis
2006-003444-30Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ustekinumab in plaque psoriasis and psoriasis (2 arms), sponsored by Janssen Biotech. Primary endpoint: PASI 75 response at Week 12. Started Feb 2007; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2006-003444-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003444-30.